Accellix Platform Chosen by the American Red Cross for Rapid and Accurate Allogeneic Source Material Characterization for Cell Therapy Development

Contributed by: Business Wire

Logo

Tags

Science

Other Science

Biotechnology

Research

Pharmaceutical

Oncology

Health

Genetics

assay cytometry point-of-need blood donor characterization leukopak lymphocyte

More Like This

PR Newswire associated0

Gift of Life Biologics and Cellex Cell Professionals GmbH Celebrate Successful Partnership to Deliver High-Quality Starting Materials for Final Drug Product Manufacturing in Cell and Gene Therapy

PR Newswire associated0

AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and other CD123 Hematological Malignancies

Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing

PR Newswire associated0

Cellply launches its end-to-end single cell potency characterization platform VivaCyte

PR Newswire associated0

The American National Red Cross Teams Up With Velico Medical In The Blood Center Education Program

The new QPS Cell Therapy Unit in Springfield, Missouri is a Leukopak collection and blood product processing center designed to meet the exponentially growing demand for blood products to support cell and gene therapy work. (Photo: Business Wire)

QPS Launches New Leukopak and Cell Therapy Products Facility

PR Newswire associated0

Solvias to Build Biologics and Cell & Gene Therapy Testing Center in Research Triangle Park

PR Newswire associated0

Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform